Skip to main content
S 1224 116th Congress Senate Health Administrative law and regulatory procedures Business ethics Civil actions and liability Competition and antitrust Drug safety, medical device, and laboratory regulation Federal Trade Commission (FTC) Licensing and registrations Public participation and lobbying

Stop STALLING Act

Introduced: April 29, 2019 Introduced by: Klobuchar, Amy Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 28, 2019
Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.
Jun 28, 2019
Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute and an amendment to the title. Without written report.
Jun 27, 2019
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Apr 29, 2019
Introduced in Senate
Apr 29, 2019
Read twice and referred to the Committee on the Judiciary.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

What's happening now June 28, 2019

Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.

 Related & companion bills 2
  • S 3384 Related bill Lowering Prescription Drug Prices for America’s Seniors and Families Act of 2020
  • HR 2374 Related bill Stop STALLING Act
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1
R
Grassley, Chuck
Iowa · Apr 29, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1224: Stop STALLING Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-1224/
MLA
"S. 1224: Stop STALLING Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-1224/.
Bluebook (legal)
S. 1224, 116th Cong. (2026), https://openamerica.io/bill/116-S-1224/.
Markdown link
[S. 1224: Stop STALLING Act](https://openamerica.io/bill/116-S-1224/)
Report a problem